Media Database
>
Gerry Smith

Gerry Smith

Media Reporter at Bloomberg News

Contact this person
Email address
g*****@*******.netGet email address
Influence score
28
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Languages
  • English
Covering topics
  • Media
  • Politics

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

bloomberg.com

Moderna Takes on Unusual FDA Request: Do Its Vaccines Cause Long Covid?

Moderna Takes on Unusual FDA Request: Do Its Vaccines Cause Long Covid?
bloomberg.com

FDA Chief Says No Plans to Put Boxed Warning on Covid Vaccines

The US Food and Drug Administration has no plans to put a “black box” warning on Covid vaccines, the agency’s top official said, despite a recent report that US regulators were preparing to add a new caution to the immunizations.
bloomberg.com

Sarepta’s Elevidys to Remain on Market With New FDA Warning

Sarepta Therapeutics Inc.’s controversial gene therapy for a rare muscle condition will remain available in the US with a strict new warning about potentially deadly liver injuries, a regulatory decision that removes the risk it would be pulled from the market.
bloomberg.com

FDA Unveils New Path for Approving Rare Disease Drugs for Just One ...

US regulators laid out new guidelines for approving custom-made treatments for individual patients, a move that could bring the promise of gene editing to more people with devastating diseases.
bloomberg.com

FDA Clears Way for Faster Personalized Gene Editing Therapy

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare diseases.
bloomberg.com

Bristol Myers Beats Quarterly Expectations on Drug Demand

Bristol Myers Squibb Co. raised its revenue outlook for the year after newer medicines outperformed expectations, easing pressure on its portfolio of aging blockbusters.
bloomberg.com

Biogen Cuts Profit Guidance After Deals to Bolster Pipeline

Biogen Inc. cut its full-year profit guidance on higher costs from deals the company has been doing to offset the decline of its aging multiple sclerosis drugs.
bloomberg.com

Do School Cellphone Bans Improve Students’ Mental Health?

Hi, it's Gerry in New York, where schools have banned smartphones in the classroom for the first time. I spoke to one high school student in a neighboring state about how a phone ban at his school has affected his mental health. But first ...
bloomberg.com

BridgeBio’s Drug for Muscle Disorder Meets Goal in Key Trial

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the way for the biotech company to seek US approval.
bloomberg.com

Intellia Pauses Gene Therapy Trials After Patient Hospitalized

Intellia Therapeutics Inc. paused clinical trials for its gene editing treatments after a patient was hospitalized with liver damage, a setback as it seeks to sell the first one-time treatment for heart and nerve conditions.
bloomberg.com

Moderna Vaccine Fails to Stop Virus Tied to Birth Defects

Moderna Inc. said its vaccine to prevent cytomegalovirus, a common cause of birth defects, failed to meet its goal in a late-stage trial, a setback for the company still struggling to move past the pandemic.